SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (196)1/20/1997 8:15:00 PM
From: Randy McWilliams   of 6136
 
Thanks for a very informative post. And just to be redundant:

BIOGEN INC. was cut to outperform from buy on Monday at Smith
Barney, according to a source at the brokerage. The firm said
Biogen was lowered to a speculative buy from a speculative
outperform because of its price. Smith Barney also lowered the
rating on BIOCHEM PHARMA INC. and AGOURON PHARMACEUTICALS INC.
BioChem was cut due to price as well as possible future news at
an conference on AIDS in Washington. Agouron was cut to a neutral
from outperform strictly on the basis of price, the firm said.
(Reuters 09:52 AM ET 01/20/97)

* Roche Holding AG said it concluded a marketing agreement with
AGOURON PHARMACEUTICALS INC. of the U.S. covering Viracept, an
anti-HIV drug co-developed by Agouron and Japan Tobacco Inc.
Terms of the agreement call for Roche to receive exclusive
marketing rights for Viracept in Europe and other countries while
Agouron retains the rights in North America and Japan Tobacco the
rights for Asia. (Reuters 08:17 AM ET 01/20/97)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News